MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jns.2013.04.016

Медицинская библиотека · Journal of the neurological sciences · 2013

A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome.

Bertolasi Laura, Frasson Emma, Turri Mara, Gajofatto Alberto, Bordignon Monia, Zanolin Elisabetta, Martini Millo, Pimazzoni Fabiana, Ferlisi Monica, Zanusso Gianluigi, Rossi Massimo, Monaco Salvatore

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод требует повторной обработки

Аннотация

OBJECTIVE

To investigate in a single-center randomized control trial whether a single IVIg course improves short-term outcome in patients with postpolio syndrome (PPS).

METHODS

Fifty-one patients with PPS were randomly allocated to receive 2g/kg IVIg body weight or placebo infused over 5 consecutive days. The primary endpoint was health-related quality of life (HRQoL) limited to the physical component score (PCS) in the Short-Form-36 (SF-36). Secondary endpoints included the SF-36 mental component score (MCS), 6-minute walk test, visual analog scale, 101-numeric rating, and fatigue severity scale. Muscle strength was graded according to the Medical Research Council scale and by dynamometer. Primary and secondary outcome variables were tested double-blind at baseline, 2months, and 4months.

RESULTS

At two months, although SF-36 PCS scores were similar in both arms, the role physical (RP) domain improved significantly in the treatment arm (p=0.05) and so did the composite MCS (p=0.015), and role emotional (RE) subscale (p=0.02). No differences were found in the remaining outcome measures. At 4months, none of the outcome variables differed significantly between groups.

CONCLUSIONS

Although the study did not reach the primary endpoint, we showed that a single IVIg course improves HRQoL related to mental activity, as measured by the SF-36 composite MCS, and role limitations including RP and RE SF-36 subscales at 2months, in patients with PPS. A single IVIg course leaves, gait, muscle strength, fatigue and bodily pain unchanged in patients with PPS.

CLASSIFICATION OF EVIDENCE: Class I evidence indicates that IVIg did not change SF-36 PCS, and Class II evidence indicates that IVIg improved scores on the SF-36 MCS, RP, and RE.

Для цитирования: Bertolasi Laura, Frasson Emma, Turri Mara, Gajofatto Alberto, Bordignon Monia, Zanolin Elisabetta, Martini Millo, Pimazzoni Fabiana, Ferlisi Monica, Zanusso Gianluigi, Rossi Massimo, Monaco Salvatore. A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome.. Journal of the neurological sciences. 2013. DOI: 10.1016/j.jns.2013.04.016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.